Evaluation for NCI Surgery Branch Clinical Research Protocols
This observational study is for people with certain cancers, including melanoma, colorectal, lung, and bladder cancer, who are being considered for treatment protocols at the National Cancer Institute Surgery Branch (NCI-SB). The NCI-SB develops experimental therapies that involve using a patient's own white blood cells to fight cancer. This study helps identify suitable candidates for these treatments by performing screening tests like lab work and scans. Researchers will also look at specific genetic information (HLA type, gene mutations, or neoantigens) in tumors to better understand these cancers. The study aims to enroll up to 7000 participants and will follow outcomes for 25 years.
- Study design
- This is an observational study designed to evaluate patients for suitability for other NCI-SB clinical research protocols. It aims to enroll up to 7000 participants.
- What's involved
- You will undergo testing and evaluations as required by the specific NCI-SB treatment protocol you are being considered for.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will track information like suitability for protocols, genetic markers, and screening test results for 25 years.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Evaluation for NCI Surgery Branch Clinical Research Protocols
At a glance
Conditions
NCT00001823
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
National Institutes of Health Clinical Center
Bethesda, Marylandstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Steven A Rosenberg, M.D. · PRINCIPAL_INVESTIGATOR · National Cancer Institute (NCI)
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of individuals suitable for NCI Surgery Branch clinical research protocols25 Years
Total number of patients who enroll on NCI Surgery Branch clinical research protocols
- Frequency of HLA type, gene specific mutations, or expression of neoantigens in malignant tumors25 years
Frequency of HLA type, gene specific mutations, or expression of neoantigens in tissue and blood samples
- Results of screening tests25 years
Results of screening tests for use on subsequent research protocol as baseline (e.g., pretreatment) values